Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2011-01-04
2011-01-04
Robinson, Hope A (Department: 1652)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S002600, C514S013800, C514S579000, C530S300000, C530S350000
Reexamination Certificate
active
07863241
ABSTRACT:
The invention provides compositions and methods for treating pulmonary conditions and for reducing the negative effects of pulmonary inflammation. Such compositions and methods employ protease inhibitors and a lung surfactant mixture. The compositions and methods can also include lipase inhibitors (e.g. a phospholipase inhibitors) and anti-oxidants.
REFERENCES:
patent: 4916117 (1990-04-01), Lezdey et al.
patent: 4938949 (1990-07-01), Borch et al.
patent: 5164369 (1992-11-01), Cochrane et al.
patent: 5260273 (1993-11-01), Cochrane et al.
patent: 5301644 (1994-04-01), Olmr
patent: 5407914 (1995-04-01), Cochrane et al.
patent: 5707634 (1998-01-01), Schmitt
patent: 5734014 (1998-03-01), Ishima et al.
patent: 5770559 (1998-06-01), Manning et al.
patent: 5780440 (1998-07-01), Lezdey et al.
patent: 5833891 (1998-11-01), Subramaniam et al.
patent: 5874029 (1999-02-01), Subramaniam et al.
patent: 5883084 (1999-03-01), Peterson et al.
patent: 5976574 (1999-11-01), Gordon
patent: 5981474 (1999-11-01), Manning et al.
patent: 5985284 (1999-11-01), Lowell
patent: 5993805 (1999-11-01), Sutton et al.
patent: 6001336 (1999-12-01), Gordon et al.
patent: 6013619 (2000-01-01), Cochrane et al.
patent: 6051257 (2000-04-01), Kodas et al.
patent: 6063138 (2000-05-01), Hanna et al.
patent: 6174496 (2001-01-01), Stein
patent: 6223455 (2001-05-01), Chickering, III et al.
patent: 6284282 (2001-09-01), Maa et al.
patent: 7053176 (2006-05-01), Hafner et al.
patent: 402068 (1990-06-01), None
patent: WO 91/00871 (1991-01-01), None
patent: WO-03/090682 (2003-11-01), None
Han et al. (Zhonghua Bing Li Xue Za Zhi, Feb. 2000, vol. 29, No. 1, pp. 43-45.
Wells, Biochemistry, vol. 29, pp. 8509-8517, 1990.
Veldhuizen et al. (Biochemistry J., 1993, vol. 295, pp. 141-147).
“International Search Report for corresponding PCT Application No. PCT/US03/12731”, (Jul. 13, 2004), 3 pgs.
“IUPAC-IUB Commission on Biochemical Nomenclature—A One-Letter Notation for Amino Acid Sequences—Tenative Rules”,The Journal of Biological Chemistry, 243(13), (1968), 3557-3559.
Bode, W., et al., “Natural Protein Proteinase Inhibitors and Their Interaction With Proteinases”,European Journal of Biochemistry, 204(2), (1992), 433-451.
Cochrane, C. G., et al., “The Efficacy and Safety of KL4-Surfactant in Preterm Infants With Respiratory Distress Syndrome”,American Journal of Respiratory and Critical Care Medicine, 153(1), (1996), 404-410.
Cochrane, C. G., “Vascular Leak in Acute Lung Injury”,American Journal of Respiratory and Critical Care Medicine, 163, 139 (Abstract Only), paper presented at the 2001 Meeting of the American Thoracic Society, (http://www.abstracts2view.com/atsall/view.php?nu=ATS1P1 1113),(2001), 1 pg.
Cowan, K. N., et al., “Complete Reversal of Fatal Pulmonary Hypertension in Rats by a Serine Elastase Inhibitor”,Nature Medicine, 6, (Jun. 2000), 698-702.
Davis, R., et al., “Aprotinin—A Review of its Pharmacology and Therapeutic Efficacy in Reducing Blood Loss Associated With Cardiac Surgery”,Drugs, 49(6), (1995), 954-983.
De Sanctis, G T., “Exogenous Surfactant Enhances Mucociliary Clearance in the Anaesthetized Dog”,European Respiratory Journal, 7(9), (Sep. 1994), 1616-21.
Delaria, K. A., “Characterization of Placental Bikunin, a Novel Serine Protease Inhibitor”,The Journal of Biological Chemistry, 272(18), (1997),12209-12214.
Dennis, M. S., et al. “Potent and Selective Kunitz Domain Inhibitors of Plasma Kallikrein Designed by Phage Display”,The Journal of Biological Chemistry, 270(43), (1995), 25411-25417.
Dietrich, W. , et al. “Reduction of Homologous Blood Requirement in Cardiac Surgery by Intraoperative Aprotinin Application—Clinical Experience in 152 Cardiac Surgical Patients”,The Thoracic and Cardiovascular Surgeon, 37, (1989), 92-98.
Enhorning, G , et al., “Increased Airway Resistance Due to Surfactant Dysfunction can be Alleviated With Aerosol Surfactant.”,Canadian Journal of Physiology and Pharmacology, 74(6), (1996), 687-691.
Enhorning, G. , et al., “Pulmonary Surfactant Maintains Patency of Conducting Airways in the Rat”,American Journal of Respiratory and Critical Care Medicine, 151(2), (1995), 554-556.
Fortes-Dias, C. L., et al., “Phospholipase A2Inhibitor From the Plasma of the South American Rattlesnake (Crotalus durissus terrificus)”,The Journal of Biological Chemistry, 269(22), (1994), 15646-15651.
Friede, M., et al., “Lyophilized Liposomes as Shelf Items for the Preparation of Immunogenic Liposome—Peptide Conjugates”,Analytical Biochemistry, 211, (1993), 117-122.
Glasser, S. W., et al., “Two SP-C Genes Encoding Human Pulmonary Surfactant Proteolipid”,The Journal of Biological Chemistry, 263(21), (1988), 10326-10331.
Hite, R D., et al., “Hydrolysis of Surfactant-Associated Phosphatidylcholine by Mammalian Secretory Phospholipases A2”,American Journal of Physiology, 275(4 Pt 1), (Oct. 1998), L740-7.
Hite, R. D., “Surfactant Deficiency in Adults”,Clinical Pulmonary Medicine, 9(1), (2002),39-45.
Hite, R D., et al., “The Spectrum of Surfactant Dysfunction in an Endobronchial Challenge Model of Asthma”,American Journal of Respiratory and Cirtical Care Medicine, 159, (1999),A333.
Ilowite, J. S., et al., “Quantitative Deposition of Aerosolized Gentamicin in Cystic Firbrosis”,American Review of Respiratory Disease, 136(6), (1987),1445-1449.
Jarjour, N N., et al., “Antigen-Induced Airway Inflammation in Atopic Subjects Generates Dysfunction of Pulmonary Surfactant”,American Journal of Respiratory and Critical Care Medicine, 160(1), (Jul. 1999), 336-41.
Jobe, A. H., “Surfactant Treatment: Experimental Basis for Clinical Use”,American Review of Respiratory Disease, 136(4), (1987),1032-1033.
Kharasch, V. S., et al., “Pulmonary Surfactant as a Vehicle for Intratracheal Delivery of Technetium Sulfur Colloid and Pentamidine in Hamster Lungs”,American Review of Respiratory Disease, 144(4), (1991),909-913.
King, R. J., et al., “Surface Active Materials from Dog Lung. II. Composition and Physiological Correlations”,American Journal of Physiology, 223(3), (1972), 715-726.
Kurashima, K , “A Pilot Study of Surfactant Inhalation in the Treatment of Asthmatic Attack”,Japan Journal of Allergology, 40(2), (Feb. 1991), 160-3.
Kurashima, K , et al., “Surface Activity of Sputum From Acute Asthmatic Patients”,American Journal of Respiratory and Critical Care Medicine, 155(4), (Apr. 1997), 1254-1259.
Laube, B. L., et al., “Homogeneity of Bronchopulmonary Distribution of99mTc Aerosol in Normal Subjects and in Cystic Fibrosis Patients”,Chest, 95(4), (1989),822-830.
Lee, C. T., et al., “Elastolytic Activity in Pulmonary Lavage Fluid From Patients With Adult Respiratory-Distress Syndrome”,The New England Journal of Medicine, 304(4), (1981),192-196.
Liu, M , et al., “Dysfunction of Guinea-Pig Pulmonary Surfactant and Type II Pneumocytes After Repetitive Challenge With Aerosolized Ovalbumin”,Clinical and Experimental Allergy, 27(7), (Jul. 1997),802-7.
Maa, Y.-F., et al., “Effect of Spray Dying and Subsequent Processing Conditions on Residual Moisture Content and Physical/Biochemical Stability of Protein Inhalation Powders”,Pharmaceutical Research, 15(5), (1998), 768-775.
Maa, Y.-F., et al., “The Effect of Operating and Formulation Variables on the Morphology of Spray-Dried Protein Particles”,Pharmaceutical Development and Technology, 2(3), (1997),213-223.
Mayer, L. D., “Influence of Vesicle Size, Lipid Composition, and Drug-to-Lipid Ratio on the Biological Activity of Liposomal Doxorubicin in Mice”,Cancer Research, 49(21), (1989), 5922-5930.
Mayer, L. D., et al., “Uptake of Adriamycin Into Large Unilamellar Vesicles in Response to a pH Gradient”,Biochmica et
Chadwick Robin A.
Fitting Thomas
Robinson Hope A
The Scripps Research Institute
Wang Hugh
LandOfFree
Compositions for treatment and prevention of pulmonary... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions for treatment and prevention of pulmonary..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions for treatment and prevention of pulmonary... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2669442